We identified seven trials, with 895 evaluable participants for this review . All provided data suitable for the primary outcome meta-analysis . One of the trials was new since the last version of this Cochrane systematic review . Risk of bias in the older, smaller studies included some unclear- or high- risk assessments, whereas we deemed the larger studies at low risk of bias . Overall, 79/452 (17%) participants allocated to corticosteroids had incomplete recovery of facial motor function six months or more after randomisation ; significantly fewer than the 125/447 (28%) in the control group ( risk ratio ( RR ) , 95% confidence interval ( CI ) to , seven trials, n = 895). The number of people who need to be treated with corticosteroids to avoid one incomplete recovery was 10 (95% CI 6 to 20). The reduction in the proportion of participants with cosmetically disabling sequelae six months after randomisation was very similar in the corticosteroid and placebo groups ( RR , 95% CI to , two trials, n = 75, low-quality evidence). However, there was a significant reduction in motor synkinesis during follow-up in participants receiving corticosteroids ( RR , 95% CI to , three trials, n = 485, moderate-quality evidence). Three studies explicitly recorded the absence of adverse effects attributable to corticosteroids. One trial reported that three participants receiving prednisolone had temporary sleep disturbances and two trials gave a detailed account of adverse effects occurring in 93 participants, all non-serious; the combined analysis of data from these three trials found no significant difference in adverse effect rates between people receiving corticosteroids and people receiving placebo ( RR , 95% CI to , n = 715).
Drugs can inhibit PCSK9, leading to lowered circulating LDL particle concentrations. Since LDL particle concentrations are a driver of cardiovascular disease like heart attacks , it is plausible that these drugs may also reduce the risk of such diseases. Clinical studies, including phase III clinical trials , are now underway to describe the effect of PCSK9 inhibition on cardiovascular disease, and the safety and efficacy profile of the drugs.      Among those inhibitors under development in December 2013 were the antibodies alirocumab , evolocumab , 1D05-IgG2 ( Merck ), RG-7652 and LY3015014, as well as the RNAi therapeutic inclisiran .  PCSK9 inhibitors are promising therapeutics for the treatment of people who exhibit statin intolerance, or as a way to bypass frequent dosage of statins for higher LDL concentration reduction.